Texas Oncology Cuts Pembrolizumab Costs Using Dosing Initiative

A new weight-based dosing program reduces drug spending by over $700,000 for Medicare Advantage patients in Texas.

Updated on Oct. 28, 2026 in Cancer

Isometric editorial illustration featuring a precision balance scale with a glass medical vial, representing pharmaceutical efficiency. — Texas Oncology and Thyme Care reduced pembrolizumab spending by $723,000 by implementing a weight-based dosing initiative for Medicare Advantage patients. AI Illustration. Upload story photo >

Live Poll

Should your local oncology providers prioritize weight-based dosing to reduce overall cancer treatment costs?

Thyme Care and Texas Oncology successfully reduced pembrolizumab expenditures by $723,000 by implementing a weight-based dosing strategy for smaller patients. This initiative resulted in a 7.3% decrease in drug utilization costs compared to traditional flat-dosing projections.

Why it matters

Flat dosing often assumes a patient weight of 100 kg, which frequently leads to medication waste when treating smaller individuals. Shifting to weight-based administration aligns with value-based care models designed to minimize total costs of care.

The initiative, which analyzed 613 total administrations, involved 115 patients switched to weight-based dosing and avoided the use of 11,800 mg of pembrolizumab. Patients weighing 80 kg or less were eligible, with specific 200 mg and 300 mg regimens applied.

The players

Thyme Care

This is a value-based cancer care company that coordinates with oncology practices to improve health outcomes and reduce costs.

Texas Oncology

This is a comprehensive cancer care organization providing oncology services throughout the state of Texas.

The details

By utilizing payer prior authorization data, the team integrated patient eligibility directly into the pharmacy workflow to target those weighing 80 kg or less. The program successfully managed 115 patients across a study group of 4,500 Medicare Advantage participants.

September 2025 marked the start of monthly weight-based dosing adherence tracking.
Adherence tracking continued through February 2026.
Adherence rates reached 48% in March 2026 and 46% in April 2026.
Results were presented at the ASCO Quality Care Symposium on October 16-17, 2026.

The Big Picture

This initiative follows the professional standards established at the ASCO Quality Care Symposium to improve clinical efficiency. It represents a significant move toward implementing weight-based protocols as a standard practice for reducing waste in specialized cancer treatments.

The initiative ensures that Medicare Advantage patients receive doses optimized for their specific body weight rather than a one-size-fits-all approach. This shift helps align healthcare costs with actual clinical need without compromising the necessary drug administration.

The takeaway

Weight-based dosing offers a clear path to reducing unnecessary medication waste in oncology treatment. Patients and providers can look for more value-based initiatives as healthcare systems continue to prioritize cost-effective treatment administration.